Filtered By:
Condition: Atrial Fibrillation
Countries: USA Health

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 257 results found since Jan 2013.

Apple Heart Study Demonstrates Ability of Wearable Technology to Detect Atrial Fibrillation
Researchers from the Stanford University School of Medicine presented preliminary results of the Apple Heart Study, an unprecedented virtual study with over 400,000 enrolled participants. The researchers reported that wearable technology can safely identify heart rate irregularities that subsequent testing confirmed to be atrial fibrillation, a leading cause of stroke and hospitalization in the United States.
Source: eHealth News EU - March 18, 2019 Category: Information Technology Tags: Featured Research Research and Development Source Type: news

Using wearable devices in clinical trials
Brandy Chittester, chief of clinical operations, IMARC Globally, more than 325 million people own wearable, connected devices, and more than 2.5 billion own smartphones. Using wearable devices in clinical trials can bring huge benefits, however, there are also concerns. Here’s a look at how researchers are using wearable devices — and what you should consider before using them in your own research. How wearable devices are advancing medicine Right now, ClinicalTrials.gov, a global database of clinical trials, lists nearly 200 trials with “wearable devices” or “wearable technology” in the description. This in...
Source: Mass Device - March 12, 2019 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog IMARC Source Type: news

Prevalence of atrial fibrillation in hospital encounters with end-stage chronic obstructive pulmonary disease on home oxygen: National trends in the United States.
CONCLUSION: AF prevalence in hospital encounters with end-stage COPD increased from 2003 to 2014. Better management strategies for end-stage COPD patients comorbid with AF are needed, especially in elderly individuals. PMID: 30684473 [PubMed - as supplied by publisher]
Source: Chest - January 23, 2019 Category: Respiratory Medicine Authors: Xiao X, Han H, Wu C, He Q, Ruan Y, Zhai Y, Gao Y, Zhao X, He J Tags: Chest Source Type: research

Geographic Disparities in the Incidence of Stroke among Patients with Atrial Fibrillation in the United States
Aim: To determine whether regional variation in stroke incidence exists among individuals with AF. Methods: Using healthcare utilization claims from 2 large US databases, MarketScan (2007-2014) and Optum Clinformatics (2009-2015), and the 2010 US population as the standard, we estimated age-, sex-, race- (only in Optum) standardized stroke incidence rates by the 9 US census divisions. We also used Poisson regression to examine incidence rate ratios (IRR) of stroke and the probability of anticoagulation prescription fills across divisions.
Source: Journal of Stroke and Cerebrovascular Diseases - December 21, 2018 Category: Neurology Authors: J'Neka S. Claxton, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, Ten é T. Lewis, Alvaro Alonso Source Type: research

Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States
ConclusionIn the real-world setting, patients with NVAF newly treated with apixaban were less likely to switch or discontinue treatment compared to patients treated with rivaroxaban or dabigatran.FundingPfizer and Bristol-Myers Squibb.
Source: Advances in Therapy - November 29, 2018 Category: Drugs & Pharmacology Source Type: research

Bariatric surgery reduces incidence of atrial fibrillation: a propensity score –matched analysis
Atrial fibrillation (AF) affects 33.5 million individuals worldwide [1] and it is estimated that the prevalence of AF in the United States will increase 2- to 3-fold over the next 50 years [2]. Patients with AF are more likely to experience a variety of negative health outcomes, including myocardial infarction, heart failure, and stroke [3,4]. In addition to these major health risks, there is a significant economic burden associated with AF, amounting to as much as $26 billion in annual healthcare expenditures in the United States alone [5].
Source: Surgery for Obesity and Related Diseases - November 24, 2018 Category: Surgery Authors: Kevin T. Lynch, J. Hunter Mehaffey, Robert B. Hawkins, Taryn E. Hassinger, Peter T. Hallowell, Jennifer L. Kirby Tags: Original article Source Type: research

Clinical Outcome Following Reinstitution of Anticoagulation after Major Gastrointestinal Bleed: A Single Institutional Analysis
Conclusion: Given the rising national trend on the use of anticoagulants for various medical necessities, it is imperative that a safe and efficient process be devised on reinstitution of anticoagulation post MGIB to guide Clinicians. Although our study represents a single institutional analysis, it concurs with recent studies that early resumption of anticoagulant following stabilization of MGIB is associated with lower thromboembolic events. Timing for resumption depends largely on the medical reason for anticoagulation; reinstitution by day 7 appear safe for patients on mechanical valve whereas after day 12 maybe approp...
Source: Blood - November 21, 2018 Category: Hematology Authors: Ezekwudo, D. E., Gaikazian, S., Anusim, N., Konde, A. S., Zakalik, D., Huben, M. T., Stender, M., Anderson, J., Jaiyesimi, I. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research

Guideline-based Management of Patients With Atrial Fibrillation
Atrial fibrillation (AF) has become a significant public health concern. An epidemiologic study conducted in 2010 estimated there are over 33.5 million people worldwide diagnosed with AF with that number predicted to rise by 5% annually. In the United States, AF is the primary diagnosis in over 500,000 hospital admissions annually. Guideline-based knowledge of treatment options is imperative in decreasing stroke risk, prevention of worsening heart function, and maintaining quality of life. It is also important for nurse practitioners to have this knowledge to make educated treatment recommendations to keep our patients saf...
Source: The Journal for Nurse Practitioners - November 20, 2018 Category: Nursing Authors: Christine Tacklind Tags: Feature Article Source Type: research

Testing and monitoring direct oral anticoagulants
Direct oral anticoagulants (DOACs) have significantly improved the care of patients requiring anticoagulation. With similar or better efficacy and safety outcomes and easier use in the outpatient setting compared with the standard-of-care vitamin K antagonists and low molecular weight heparin, DOACs are now endorsed as first-line treatment of indications including prevention of stroke and systemic embolism in nonvalvular atrial fibrillation and treatment of venous thromboembolism. DOACs are easy-to-use oral agents that offer simple dosing and short half-lives, with no need to test levels because of the wide therapeutic win...
Source: Blood - November 8, 2018 Category: Hematology Authors: Connors, J. M. Tags: Perspectives, Thrombosis and Hemostasis Source Type: research

Dabigatran - the First Approved DTI for SPAF.
Authors: Trailokya A, Hiremath JS Abstract Atrial fibrillation (AF) is commonly occurring arrhythmia in clinical practice. AF is easy to recognize but difficult to treat. Stroke is the most devastating complication of AF and is associated with a huge disease burden on the society. Effective stroke prevention is a priority for patients with AF. Two-thirds of strokes due to AF are preventable with suitable anticoagulant therapy. VKA like warfarin, acenocoumarol remains the gold standard for stroke prevention in AF (SPAF). However, it is associated with numerous limitations such as a high risk of drug-drug, drug-food ...
Source: Journal of the Association of Physicians of India - October 25, 2018 Category: General Medicine Tags: J Assoc Physicians India Source Type: research

Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications
Atrial fibrillation is the most common arrhythmia in the United States and affects between 2.7 million and 6.1 million adults in the United States, with a lifetime risk of up to 1 in 4 adults over age 40 and a prevalence that is projected to double over the next 25 years.1,2 Though warfarin has long been the cornerstone of therapy to reduce the risk of stroke, several new direct oral anticoagulants (DOACs) have recently become available, beginning with FDA approval of dabigatran in October 2010, and followed by rivaroxaban in 2011, apixaban in 2014, and most recently edoxaban in 2015.
Source: The American Journal of Medicine - October 3, 2018 Category: General Medicine Authors: Benjamin A. Rodwin, Joseph A. Salami, Erica S. Spatz, Javier Valero-Elizondo, Salim S. Virani, Ron Blankstein, Michael J. Blaha, Khurram Nasir, Nihar R. Desai Tags: Clinical Research Study Source Type: research

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).
Conclusions: The cumulative burden of HCM is substantial and dominated by heart failure and atrial fibrillation occurring many years following diagnosis. Young age of diagnosis and the presence of a sarcomere mutation are powerful predictors of adverse outcomes. These findings highlight the need for close surveillance throughout life, and the need to develop disease-modifying therapies. PMID: 30297972 [PubMed - in process]
Source: Circulation - October 2, 2018 Category: Cardiology Authors: Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I Tags: Circulation Source Type: research

EP News: Allied Professionals
Using data on patients in the United States Renal Data System (USRDS), Siontis et  al (Circulation 2018; https://doi.org/10.1161/CIRCULATIONAHA.118.035418 [Epub ahead of print], PMID 29954737) sought to assess patterns of apixaban use and outcomes related to use of anticoagulants in patients with end-stage renal disease (ESRD) and atrial fibrillation (AF). As background, patient s with ESRD have both higher risk of bleeding and higher risk of stroke with AF. The Food and Drug Administration has approved updated labeling for the use of apixaban in patients with ESRD on the basis of a small pharmacokinetic study.
Source: Heart Rhythm - July 26, 2018 Category: Cardiology Authors: Erica S. Zado Tags: EP News Source Type: research

Stroke Prevention for High-Risk Atrial Fibrillation in the Emergency Setting: Differences Between Canada and the United States
Publication date: July 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 7Author(s): Bory Kea, Benjamin C. Sun, David R. Vinson
Source: Canadian Journal of Cardiology - July 10, 2018 Category: Cardiology Source Type: research